Papp KA, et al. - In this randomized, placebo-controlled trials, researchers analyzed 2081 individuals to estimate the effectiveness of tildrakizumab (tildrakizumab 100 mg and tildrakizumab 200 mg vs placebo groups) in plaque psoriasis cases. At week 12, they observed better proportions of Psoriasis Area and Severity Index (PASI) 75 responders with tildrakizumab 100 mg (62.3%) and tildrakizumab 200 mg (64.8%) vs placebo (5.6%) and for PASI 90, PASI 100 and Physician's Global Assessment (PGA) 'clear' or 'minimal' vs placebo. Higher PASI 90, PASI 100 and PGA responses were observed in subjects without prior biologics. They predicted PASI 90 response with week 8 PASI 50 response.